GlassScriptPhysician profile
Michael S Lyerly
NPI 1851682694
$4,153.16
in general payments reported to CMS, 2019-2025
35 companies · $169 in 2025
The $169 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,656 · 2020: $697 · 2021: $749 · 2022: $314 · 2023: $219 · 2024: $349 · 2025: $169.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $737.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $736.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $468.83 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $381.80 | 2019-2021 | |
| Novo Nordisk INC | $369.11 | 2019-2025 | Ozempic |
| Pfizer INC. | $351.96 | 2019-2023 | |
| Amgen INC. | $330.46 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $243.87 | 2019-2022 | |
| Allergan, INC. | $225.76 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $223.53 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $187.68 | 2021-2023 | Jardiance |
| Merck Sharp & Dohme LLC | $162.04 | 2019-2023 | Dificid, Zerbaxa, Recarbrio |
| Takeda Pharmaceuticals U.S.A., INC. | $153.55 | 2019-2022 | |
| Lilly USA, LLC | $134.07 | 2020-2021 | |
| Abbott Laboratories | $131.65 | 2021-2024 | Freestyle Libre 3 |
| Medtronic, INC. | $126.64 | 2024 | Signia |
| Glaxosmithkline, LLC. | $102.14 | 2019-2025 | Trelegy Ellipta |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $97.56 | 2023-2025 | |
| Astellas Pharma US INC | $79.53 | 2019 | |
| Scpharmaceuticals INC. | $45.20 | 2024 | |
| Biohaven Pharmaceuticals, INC. | $32.14 | 2021 | |
| Ironshore Pharmaceuticals INC. | $31.60 | 2019 | |
| Mdd US Operations, LLC | $30.11 | 2019 | |
| Sunovion Pharmaceuticals INC. | $27.31 | 2020 | |
| Shire North American Group INC | $25.11 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $24.33 | 2024 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $23.12 | 2019-2020 | |
| Amarin Pharma, INC. | $22.19 | 2020 | |
| Edwards Lifesciences Corporation | $18.21 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Teva Pharmaceuticals USA, INC. | $16.35 | 2019 | |
| Mylan Specialty L.P. | $13.79 | 2019 | |
| Dexcom, INC. | $13.76 | 2021 | |
| Ironwood Pharmaceuticals, INC | $13.56 | 2019 | |
| Esperion Therapeutics, INC. | $12.26 | 2021 | |
| Nestle Healthcare Nutrition INC. | $11.63 | 2021 | |
| Eisai INC. | $11.20 | 2021 | |
| Sanofi-Aventis U.S. LLC | $11.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Lyerly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.